Skip to content

Diagnose HFpEF with confidence

Precision detection of heart failure with preserved ejection fraction (HFpEF).

Keep me up to date

The greatest unmet need in cardiovascular medicine

With a rising population of heart failure patients putting unprecedented stress on the medical system, this “greatest unmet need in cardiovascular medicine” requires innovative and groundbreaking precision treatment strategies. 7

50% of heart failure patients have HFpEF

Heart failure-related costs and cases are expected to double by 2030.1

50% of heart failure patients have HFpEF

Up to 75% of HFpEF patients are a missed diagnosis

Missed diagnoses lead to increased hospitalizations and mortality.2

Up to 75% of HFpEF patients are a missed diagnosis

Half of all heart failure patients suffer from HFpEF. Understanding what it is, when it happens, and how to treat it remains the single largest unmet need in cardiovascular health.

Dr. Norman Stockbridge, Director of the Division of Cardiology and Nephrology at the Office of Cardiology, Hematology, Endocrinology and Nephrology at the U.S. Food and Drug Administration (FDA). 5

FNIH

 

Precision HFpEF detection

EchoGo Heart Failure, built in collaboration with the Mayo Clinic, delivers precision heart failure detection using the power of AI from a single apical 4-chamber view of an echocardiogram. 

  • 90% accuracy in detecting HFpEF 3
  • 25% increase in diagnostic accuracy from current clinical practice 3
  • Reduced need for costly and invasive procedures 3

"It has been a pleasure to collaborate with the team at Ultromics to develop and test EchoGo Heart Failure. This novel solution applies AI to cardiovascular imaging to greatly simplify identification of patients with HFpEF, a diagnosis that can be challenging to make, and allow more expeditious treatment.  HFpEF currently is associated with high rates of hospitalization and mortality. By facilitating early diagnosis and treatment, we can improve the lives of many.”

 

Patricia A. Pellikka, MD. 

Vice Chair, Department of Cardiovascular Medicine at Mayo Clinic
 

Mayo-clinic-banner

With recent advances in drug therapies that positively impact HFpEF outcomes, such as Sodium-glucose Cotransporter-2 (SGLT2) Inhibitors, it’s more important than ever to provide a fast and accurate HFpEF diagnosis. 4 


But current clinical practices require time and skill to accurately predict outcomes, and even then, HFpEF can be missed. 

EchoGo Heart Failure significantly reduces reporting time while improving accuracy, ultimately limiting the need for costly and more invasive procedures.6

Pioneering technology

Accurate

>90% accurate in detecting HFpEF.

Accurate

Efficient

Requires only an echocardiographic Apical 4-Chamber Loop.

Efficient

Vendor neutral

Connects with any system, anywhere.

Vendor neutral

Accessible

Cloud-based service accessible to all providers.

Accessible

Quality

Ensure patients get the life-extending and life-saving treatment they need.

Quality

*EchoGo Heart Failure is pending FDA 510k clearance

References:

  1. Urbich M, et al. PharmacoEconomics. 2020;38:1219-1236
  2. Sanders van-Wijk, et al. Eur J Heart Fail. 2020;23:838-840
  3. EchoGo Heart Failure FDA Submission
  4. Heidenreich PA, et al. JACC. 2022;79:263-421
  5. [FNIH Press Release]
  6. Human vs Artificial Intelligence-Based Echocardiography Analysis as Predictor of Outcomes: An analysis from the World Alliance Societies of Echocardiography COVID.
  7. Shah SJ, et al. Circulation. 2020;141:1001–1026.

   

 

Sign up for news

Get notified when available